Applied Therapeutics Inc at Cowen Health Care Conference Transcript
Welcome back to the 43rd Annual TD Health Care Conference. I'm Marc Frahm from the biotech team. I'm joined by my colleagues, [Paten Bundestag], [Nigel Scott], over here as well as we have four companies on this panel that focus on neuromuscular and bone, orphan diseases.
So we've got from Applied Therapeutics, Shoshana Shindelman, Founder and CEO. From Entrada Therapeutics, Nathan Dowden, the COO. And then from Inozyme, Axel Bolte, CEO. Rallybio, Martin Mackey, the CEO.
The plan is to start off with some general questions that are [schematic] across -- mostly orphan disease, more generally than even just neuromuscular and bone, and then eventually move into more company-specific questions. We're also more than open to taking questions from the audience. You can submit those by submitting to Salon G at cowen.com. And they'll come up here and we'll try to put those into the list as well.
Maybe to start off with -- several companies on this panel are developing therapies that are not uncommon to rare diseases where there's no
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |